We recently compiled a list of the Billionaire Israel Englander’s Top 10 Stock Picks Heading Into 2025. In this article, we ...

Eli Lilly and Company has invested more than $20 billion in its manufacturing capabilities since 2020 to help meet high ...

High Return on Equity: With a three-year average ROE of 101% and an ROE of 123% in the last year, the company has ...

The board of Eli Lilly and Company ( NYSE:LLY ) has announced that it will be paying its dividend of $1.50 on the ...

Chris Schott, an analyst from J.P. Morgan, maintained the Buy rating on Eli Lilly & Co (LLY – Research Report). The associated price target ...

Here are some clinical trials that could send Big Pharma shares soaring, or crashing, in 2025. Eli Lilly. The world’s biggest ...

Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved Zepbound® (tirzepatide) as the first and only prescription medicine for adults with moderate ...

Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for ...

Comparing Tyrzepatide and Semaglutide in the slimming drug market, with potential growth driven by increasing obesity rates worldwide. Explore more here.

Eli Lilly's stock has been a strong winner over the past few years, powered by its portfolio of glucagon-like peptide-1 ...

LY-4052031 is under clinical development by Eli Lilly and Co and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase I drugs for Ovarian Cancer have a 73% phase transition success ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other pharma dividend stocks. The pharmaceutical industry in 2024 faced a relatively quiet ...